证券代码：832735 证券简称：德源药业 公告编号：2025-040 江苏德源药业股份有限公司 投资者关系活动记录表 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带 法律责任。 一、 投资者关系活动类别 二、 投资者关系活动情况 活动时间：2025 年 5 月 26 日 活动地点：江苏省连云港市连云区大浦工业区金桥路 21 号公司三楼会议室 参会单位及人员：华夏基金、信达证券（排名不分先后） 上市公司接待人员：公司董事长、总经理：陈学民先生；公司副总经理、董事 会秘书、财务负责人：王齐兵先生；公司副总经理、研究所所长：杨汉跃先生。 三、 投资者关系活动主要内容 公司组织调研单位实地参观一工厂制剂车间、二工厂研究所、三工厂原料药车 间，了解生产与研发情况。管理层系统介绍经营状况和产品研发，深化调研单位对 1 / 2 公司的认知。此外，本场交流活动就调研单位关心的问题进行沟通与交流，主要问 题及回复情况如下： 问题 1：介绍一下公司创新药 DYX116 的情况。 回复：DYX116 是公司与上海药明康德新药开发有限公 ...

证券代码：832735 证券简称：德源药业 公告编号：2025-039 江苏德源药业股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 江苏德源药业股份有限公司 2024 年年度权益分派方案已获 2025 年 4 月 25 日 召开的股东会审议通过，本次实施分配方案距离股东会审议通过的时间未超过两 个月。 现将权益分派事宜公告如下： 1 / 3 （2）对合格境外投资者股东，根据国税函[2009]47 号，公司按 10%的税率代 扣代缴所得税后，实际每 10 股派发 4.14 元。 （3）对于合格境外投资者之外的其他机构投资者和法人股东，本公司未代扣 代缴所得税，由纳税人在所得发生地缴纳。 二、权益登记日与除权除息日 本次权益分派权益登记日为：2025 年 5 月 28 日 除权除息日为：2025 年 5 月 29 日 三、权益分派对象 本次权益分派基准日合并报表归属于母公司的未分配利润为 583,779,230.49 元，母公司未分配利润为 583,047,0 ...

证券代码：832735 证券简称：德源药业 公告编号：2025-037 江苏德源药业股份有限公司 简式权益变动报告书 信息披露义务人及其主要负责人保证公告内容的真实、准确和完整，不存在 虚假记载、误导性陈述或者重大遗漏。 信息披露义务人保证除本报告书披露的信息外，没有通过任何其他方式增加 或减少其在上市公司中拥有权益的股份。 上市公司：江苏德源药业股份有限公司 股票上市地点：北京证券交易所 股票简称：德源药业 股票代码：832735 信息披露义务人：任路 住所：连云港市海州区****** 通讯地址：连云港市海州区****** 权益变动性质：股份减少 1 / 14 信息披露义务人声明 一、本报告书系信息披露义务人根据《中华人民共和国公司法》《中华人民共 和国证券法》《上市公司收购管理办法》《北京证券交易所股票上市规则》《公开发 行证券的公司信息披露内容与格式准则第 55 号——北京证券交易所上市公司权益 变动报告书、上市公司收购报告书、要约收购报告书、被收购公司董事会报告书》 及其他相关法律、法规和部门规章的有关规定编写。 第一节 释义 4 / 14 二、信息披露义务人签署本报告已获得必要的授权和批准，其履行亦 ...

证券代码：832735 证券简称：德源药业 公告编号：2025-038 江苏德源药业股份有限公司 持股 5%以上股东权益变动达到 5%的提示性公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 江苏德源药业股份有限公司（以下简称"公司"）于 2025 年 5 月 15 日收到 持股 5%以上股东任路出具的《股份减持进展告知函》。上述股东于 2025 年 3 月 21 日至 2025 年 5 月 15 日期间通过集中竞价方式累计减持公司股份 639,491 股， 导致其合计持有公司的股份比例从 5.817621%减少至 4.999969%，权益变动触及 5%的情形。现将其有关权益变动情况公告如下： 一、本次权益变动基本情况 （一）信息披露义务人基本情况 | 1、基本情况 | | | | | --- | --- | --- | --- | | 信息披露义务人 | | 任路 | | | 持股变动时间 | | 年 月 日至 2025 3 21 | 年 月 日 2025 5 15 | | 股票简称 | 德源药业 ...

证券代码：832735 证券简称：德源药业 公告编号：2025-036 关于西格列汀二甲双胍缓释片 获国家药监局签发药品注册证书的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 2025 年 5 月 9 日，江苏德源药业股份有限公司（以下简称"公司"）按照化 学药品 3 类申报的西格列汀二甲双胍缓释片收到国家药品监督管理局（NMPA） 核准签发的药品注册证书，且视同通过一致性评价。 一、 药品基本情况 江苏德源药业股份有限公司 1.药品名称：西格列汀二甲双胍缓释片 剂型：片剂 规格：磷酸西格列汀 100mg（以 C16H15F6N5O 计）和盐酸二甲双胍 1000mg 注册分类：化学药品 3 类 批准文号：国药准字 H20254043 药品生产企业：江苏德源药业股份有限公司 2.药品其他情况 本次西格列汀二甲双胍缓释片的获批，进一步丰富了公司在糖尿病领域的产 品管线，并与现有糖尿病领域产品形成协同效应，巩固并提升公司在糖尿病领域 的品牌效应和市场竞争力。 西格列汀二甲双胍缓释片是由西格列汀和二甲双 ...

Investment Rating - The investment rating for the company is "Outperform" (maintained) [1][3] Core Views - The first subject of the Phase I clinical trial for the innovative drug DYX116 has been enrolled, with expectations to enter Phase II in Q1 2026 if progress continues smoothly [3] - The company maintains its profit forecast for 2025-2027, expecting net profits attributable to the parent company to be 178 million, 202 million, and 226 million yuan respectively, with corresponding EPS of 2.28, 2.58, and 2.88 yuan per share [3] - DYX116 is a triple-target peptide that regulates glucose and lipid metabolism, showing superior effects in lowering blood sugar, reducing weight, and alleviating fatty liver compared to dual-target products [4] Financial Summary - The total revenue for 2023 was 709 million yuan, with a year-on-year growth of 11.7%. The projected revenues for 2024, 2025, 2026, and 2027 are 868 million, 960 million, 1,062 million, and 1,191 million yuan respectively, with growth rates of 22.5%, 10.5%, 10.7%, and 12.2% [7][9] - The net profit attributable to the parent company for 2023 was 138 million yuan, with a year-on-year growth of 14.4%. The projected net profits for the following years are 177 million, 178 million, 202 million, and 226 million yuan, with growth rates of 28.3%, 0.8%, 13.1%, and 11.8% [7][9] - The gross margin for 2023 was 81.9%, expected to be 84.6% in 2024, and around 83% in the following years [10] Research and Development - The company invested 116.96 million yuan in R&D in 2024, a 6.75% increase from 2023. It has 12 products currently under review by the CDE, with plans to submit 10 new projects in 2025 [5][9]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a total revenue of 868 million yuan for 2024, representing a year-on-year growth of 22.46%, and a net profit of 177 million yuan, up 28.26% year-on-year [5] - The company's gross margin improved to 84.56%, an increase of 2.69 percentage points compared to 2023, indicating strong operational quality [5] - The sales of core products "Furuitong" and "Bokaiqing" saw significant growth, with sales revenue increasing by 26.17% compared to 2023, contributing to the overall revenue growth [7] - The company has a robust pipeline for new drug development, with a total of over 30 products under research, and has successfully obtained multiple drug registration certificates [8] Summary by Sections Financial Performance - The company achieved a net operating cash flow of 116 million yuan, a year-on-year increase of 23.4%, reflecting stable operational quality [5] - The projected revenues for 2025-2027 are 1,055.79 million yuan, 1,209.62 million yuan, and 1,451.55 million yuan, with respective growth rates of 21.57%, 14.57%, and 20.00% [9] - The projected net profits for the same period are 228.73 million yuan, 266.35 million yuan, and 313.23 million yuan, with growth rates of 29.24%, 16.45%, and 17.60% [9] Market Position and Strategy - The company has effectively optimized its cost structure and improved its product sales mix, leading to enhanced profitability [7] - The company is focusing on chronic disease markets, particularly diabetes and hypertension, which together accounted for 98.81% of total revenue [7] - The company is also making significant strides in emerging fields, with revenue from peripheral nerve and rare disease drugs increasing by over 130% year-on-year [7] Research and Development - The company invested 116.96 million yuan in R&D in 2024, a 6.74% increase from 2023, supporting its innovation-driven strategy [8] - The company has established partnerships with research institutions to explore new paths for innovative drug development [8] - The company aims to approve approximately seven new products annually from 2025 to 2027, further enriching its generic drug portfolio [8]

Group 1: Financial Performance - In 2024, the company achieved operating revenue of 86,846.46 million yuan, a year-on-year increase of 22.46% [6] - Net profit for 2024 was 17,698.34 million yuan, up 28.26% year-on-year; net profit after deducting non-recurring gains and losses was 16,959.51 million yuan, a 35.23% increase [6] - Operating cash flow for 2024 reached 11,632.20 million yuan, growing by 23.40% compared to the previous year [6] - Total assets at the end of the reporting period were 138,441.38 million yuan, a 19.95% increase year-on-year; total liabilities were 27,847.52 million yuan, up 35.31% [6] - The company's equity totaled 110,593.86 million yuan, reflecting a 16.62% increase year-on-year [6] - The asset-liability ratio increased to 20.12% from 17.83% at the end of the previous year [6] Group 2: Research and Development - In 2024, the company invested 11,696.48 million yuan in R&D, a 6.75% increase from the previous year [7] - The company obtained 7 drug registration certificates for generic drugs in 2024, with 3 more in 2025, totaling 12 products under CDE review [7] - The innovative drug DYX116 received clinical trial approval in December 2024, with plans to advance to Phase II trials in Q1 2026 if progress is smooth [9] [12] - R&D expenses for 2022, 2023, and 2024 were 6,469.91 million yuan, 10,956.67 million yuan, and 11,696.48 million yuan respectively, all expensed in the current period without capitalization [11] Group 3: Market Expansion and Sales Strategy - The company plans to expand its market in 2025 by focusing on academic promotion and retail channel development, particularly in grassroots medical institutions [9] - Continued growth is expected for products like复瑞彤 and 波开清, with increased sales efforts for other products [9] - The company aims to explore new and emerging markets to create new growth points [9] Group 4: Investor Relations and Shareholder Returns - Since its listing on the New Third Board in 2015, the company has consistently paid cash dividends, totaling 13,607.03 million yuan, with a proposed dividend of 3,597.69 million yuan for this year [7] - The company has established various management systems to protect investor rights and enhance information disclosure quality [7]

开源证券股份有限公司（以下简称"开源证券"或"保荐机构"）作为江苏 德源药业股份有限公司（以下简称"德源药业"、"公司"、"上市公司"或"发行 人"）向不特定合格投资者公开发行股票的保荐机构，履行持续督导职责期限至 2024 年 12 月 31 日。截至本说明出具日，本次发行持续督导期已届满，现根据 《证券发行上市保荐业务管理办法》《北京证券交易所股票上市规则（试行）》《北 京证券交易所证券发行上市保荐业务管理细则》等相关规定，保荐机构出具本保 荐工作总结报告书。 | 公司名称 | 江苏德源药业股份有限公司 | | --- | --- | | 证券简称 | 德源药业 | | 证券代码 | 832735 | | 法定代表人 | 陈学民 | | 成立日期 | 2004 年 10 月 29 日 | | 注册资本 | 78,210,660.00 元 | | 注册地址 | 江苏省连云港市经济技术开发区长江路 号 29 | | 办公地址 | 江苏省连云港市经济技术开发区长江路 号 29 | | 董事会秘书 | 王齐兵 | | 联系电话 | 0518-82342975 | | 本次证券发行类型 | 向不特定合格投资者公开发 ...

证券代码：832735 证券简称：德源药业 公告编号：2025-029 （二）会议召开地点 江苏德源药业股份有限公司 2024 年年度报告业绩说明会预告公告 本次业绩说明会将采用网络远程的方式举行，投资者可登陆全景网"投资者 关系互动平台"（http://ir.p5w.net）参与本次业绩说明会。 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 说明会类型 江苏德源药业股份有限公司（以下简称"公司"）于 2025 年 3 月 31 日在北 京证券交易所信息披露平台（www.bse.cn）披露了《2024 年年度报告》（公告编 号：2025-019）和《2024 年年度报告摘要》（公告编号：2025-020），为方便广大 投资者更深入了解公司 2024 年年度经营业绩的具体情况，加强与投资者的互动 交流，公司拟召开 2024 年年度报告业绩说明会。 二、 说明会召开的时间、地点 （一）会议召开时间：2025 年 4 月 14 日（星期一）15:00 至 16:30。 三、 参加人员 为充分尊重投资者 ...